Tags

Type your tag names separated by a space and hit enter

A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome.
BMC Gastroenterol 2009; 9:15BG

Abstract

BACKGROUND

Irritable Bowel Syndrome (IBS) is a common chronic gastrointestinal disorder and the evidence for efficacy of most drug therapies in the treatment of IBS is weak. A popular alternative is probiotics, which have been used in several conditions. including IBS. Probiotics are live microbial food supplements.The aim of this systematic review and meta-analysis of randomized trials study was to evaluate the efficacy of probiotics in alleviating symptoms in patients with irritable bowel syndrome. We searched Ovid versions of MEDLINE (1950-2007), EMBASE (1980-2007), CINAHL (1982-2007), AMED (1985-2007), the Cochrane library and hand searched retrieved papers.

RESULTS

We identified 14 randomized placebo controlled trials. Combined data suggested a modest improvement in overall symptoms after several weeks of treatment: for dichotomous data from seven trials the overall Odds Ratio (OR) was 1.6 (95% CI, 1.2 to 2.2); for continuous data from six trials the standardised mean difference (SMD) was 0.23 (95% CI, 0.07 to 0.38).For individual symptoms the results differed between the pooled dichotomous and pooled continuous data. Trials varied in relation to the length of treatment (4-26 weeks), dose, organisms and strengths of probiotics used.

CONCLUSION

Probiotics may have a role in alleviating some of the symptoms of IBS, a condition for which currently evidence of efficacy of drug therapies is weak. However, as IBS is a condition that is chronic and usually intermittent longer term trials are recommended. Such research should focus on the type, optimal dose of probiotics and the subgroups of patients who are likely to benefit the most.

Authors+Show Affiliations

Department of Primary Health Care, Centre for Evidence Based Medicine, University of Oxford, Rosemary Rue Building, Old Road Campus, Headington, Oxford, UK. n.hoveyda@doctors.org.ukNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis
Review
Systematic Review

Language

eng

PubMed ID

19220890

Citation

Hoveyda, Nourieh, et al. "A Systematic Review and Meta-analysis: Probiotics in the Treatment of Irritable Bowel Syndrome." BMC Gastroenterology, vol. 9, 2009, p. 15.
Hoveyda N, Heneghan C, Mahtani KR, et al. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol. 2009;9:15.
Hoveyda, N., Heneghan, C., Mahtani, K. R., Perera, R., Roberts, N., & Glasziou, P. (2009). A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterology, 9, p. 15. doi:10.1186/1471-230X-9-15.
Hoveyda N, et al. A Systematic Review and Meta-analysis: Probiotics in the Treatment of Irritable Bowel Syndrome. BMC Gastroenterol. 2009 Feb 16;9:15. PubMed PMID: 19220890.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. AU - Hoveyda,Nourieh, AU - Heneghan,Carl, AU - Mahtani,Kamal R, AU - Perera,Rafael, AU - Roberts,Nia, AU - Glasziou,Paul, Y1 - 2009/02/16/ PY - 2008/05/18/received PY - 2009/02/16/accepted PY - 2009/2/18/entrez PY - 2009/2/18/pubmed PY - 2009/5/6/medline SP - 15 EP - 15 JF - BMC gastroenterology JO - BMC Gastroenterol VL - 9 N2 - BACKGROUND: Irritable Bowel Syndrome (IBS) is a common chronic gastrointestinal disorder and the evidence for efficacy of most drug therapies in the treatment of IBS is weak. A popular alternative is probiotics, which have been used in several conditions. including IBS. Probiotics are live microbial food supplements.The aim of this systematic review and meta-analysis of randomized trials study was to evaluate the efficacy of probiotics in alleviating symptoms in patients with irritable bowel syndrome. We searched Ovid versions of MEDLINE (1950-2007), EMBASE (1980-2007), CINAHL (1982-2007), AMED (1985-2007), the Cochrane library and hand searched retrieved papers. RESULTS: We identified 14 randomized placebo controlled trials. Combined data suggested a modest improvement in overall symptoms after several weeks of treatment: for dichotomous data from seven trials the overall Odds Ratio (OR) was 1.6 (95% CI, 1.2 to 2.2); for continuous data from six trials the standardised mean difference (SMD) was 0.23 (95% CI, 0.07 to 0.38).For individual symptoms the results differed between the pooled dichotomous and pooled continuous data. Trials varied in relation to the length of treatment (4-26 weeks), dose, organisms and strengths of probiotics used. CONCLUSION: Probiotics may have a role in alleviating some of the symptoms of IBS, a condition for which currently evidence of efficacy of drug therapies is weak. However, as IBS is a condition that is chronic and usually intermittent longer term trials are recommended. Such research should focus on the type, optimal dose of probiotics and the subgroups of patients who are likely to benefit the most. SN - 1471-230X UR - https://www.unboundmedicine.com/medline/citation/19220890/A_systematic_review_and_meta_analysis:_probiotics_in_the_treatment_of_irritable_bowel_syndrome_ L2 - https://bmcgastroenterol.biomedcentral.com/articles/10.1186/1471-230X-9-15 DB - PRIME DP - Unbound Medicine ER -